As of 2025-04-22, the Intrinsic Value of GT Biopharma Inc (GTBP) is -24.31 USD. This GTBP valuation is based on the model Peter Lynch Fair Value. With the current market price of 2.17 USD, the upside of GT Biopharma Inc is -1,220.23%.
Based on its market price of 2.17 USD and our intrinsic valuation, GT Biopharma Inc (GTBP) is overvalued by 1,220.23%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -24.31 - -24.31 | -24.31 | -1,220.23% |
| P/E | (132.05) - (231.71) | (160.68) | -7504.7% |
| DDM - Stable | (35.68) - (108.51) | (72.09) | -3422.3% |
| DDM - Multi | (31.99) - (78.75) | (45.86) | -2213.4% |
| Market Cap (mil) | 5.51 |
| Beta | 0.77 |
| Outstanding shares (mil) | 2.54 |
| Enterprise Value (mil) | 1.56 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.79% |
| Cost of Debt | 5.00% |
| WACC | 7.23% |